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Abstract The purpose of these analyses was to characterize
demographic and baseline clinical characteristics of Latin
American patients with Fabry disease compared to that of
patients in the rest of the world. Observational data reported
to the Fabry Registry were obtained from untreated patients
or prior to treatment with enzyme replacement therapy. As of
October 1, 2010, 3,752 patients were enrolled in the Fabry
Registry worldwide, including 333 patients within Latin
America. Latin American patients tended to be younger than
Fabry Registry patients enrolled in the rest of the world:
mean current age 35.5 years versus 39.2 years for men
(p < 0.05 by t-test), mean age 37.8 years versus 43.6 years
for women (p < 0.05 by t-test). A smaller percentage of
Latin American patients have received enzyme replacement
therapy, compared to patients in the rest of the world: 67%
versus 80% for men, and 19% versus 39% of women,
respectively. Thirty-one percent of men and 22% of women
in Latin America reported experiencing a significant cardio-
vascular, renal, or cerebrovascular event, at a mean age of
35  12.6 years in men and 44  12.3 years in women.
Cardiovascular events were the most common type of initial
clinical event among men and women in Latin America. The
medical community in Latin America should be aware of
Fabry disease as a possible cause of renal or cardiac
dysfunction. Increased awareness will facilitate prompt
diagnosis and initiation of treatment.
Background
Fabry disease is a rare X-linked lysosomal storage disorder
caused by decreased or absent activity of the enzyme
a-galactosidase A (a-Gal A) (Brady et al. 1967). This
condition results in the accumulation of glycolipids – mainly
globotriaosylceramide (GL-3) in lysosomes from endothelial
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cells, fibroblasts, pericytes from dermal tissue, heart, kidney,
and the autonomic nervous system (Desnick et al. 2001;
Kolodny and Pastores 2002). The global incidence of Fabry
disease is has been estimated as 1:40,000 males (Desnick
et al. 2001) and as 1:117,000 in the general population
(Meikle et al. 1999). However, patients who have atypical or
few symptoms may not be diagnosed with Fabry disease,
which makes it difficult to determine a precise incidence or
prevalance of the disease. . Furthermore, newborn screening
studies have suggested that the prevalence of various types
of mutations in the gene encoding a-Gal A may actually be
much higher (for review, see [Germain 2010]).
Because Fabry disease is X-linked, men usually experi-
ence more severe manifestations than women (Desnick et al.
2001). However, a significant portion of heterozygous
women also develop symptoms (Wilcox et al. 2008). The
first symptoms of Fabry disease often appear during
childhood, including acroparesthesias, abdominal pain, diar-
rhea, hypohidrosis or anhidrosis, corneal verticillata, and
angiokeratoma (Desnick et al. 2001; Hopkin et al. 2008;
Nguyen et al. 2005). The most serious complications of
Fabry disease, including renal failure, cardiovascular events,
and stroke usually manifest during adulthood (Desnick et al.
2001; Germain 2010; Wilcox et al. 2008). The increased
availability of renal replacement therapy over the past several
decades has extended the lifespan of Fabry patients (Branton
et al. 2002; Mehta et al. 2009; Waldek et al. 2010).
Cardiovascular disease is now the most commonly reported
cause of death among both men and women with Fabry
disease (Mehta et al. 2009; Waldek et al. 2010). The life
expectancy (calculated from birth) for patients with Fabry
disease is 58.2 years for men and 75.4 years for women,
respectively (Waldeck et al. 2009).
The clinical diagnosis of Fabry disease can be difficult,
because its signs and symptoms are often mistaken for
other, more common diseases. In males, the demonstration
of deficient enzymatic activity of a-galactosidase A in
plasma or leukocytes can be used to confirm diagnosis
(Brady et al. 1967). Enzyme activity can also be analyzed
in dried blood spots on filter paper (Chamoles et al. 2001),
which facilitates the screening of large populations.
However, positive results obtained by this method should
be corroborated by analysis of enzyme activity in plasma or
leukocytes. Measurement of enzymatic activity is less
useful in female heterozygotes, who often have a-galacto-
sidase A activity levels within the normal range. Genotyp-
ing should be used for diagnostic confirmation in
heterozygous females (Linthorst et al. 2008). Furthermore,
it is important that physicians obtain a complete medical
history and perform a detailed pedigree analysis as the
adverse consequences associated with delayed diagnosis
include not only medical morbidity, but also psychological
damage, loss of educational opportunities, and loss of
economic productivity (Gold et al. 2002; Cole et al. 2007).
Currently, the only specific treatment for Fabry disease is
enzyme replacement therapy (ERT) with recombinant
human a-Gal A (Eng et al. 2001; Schiffmann et al. 2001).
Two forms of ERT are commercially available: agalsidase
alfa (Shire Human Genetic Therapies, Inc. Cambridge, MA,
USA) and agalsidase beta (Genzyme, a Sanofi company,
Cambridge, MA, USA). The Fabry Registry is a global
observational database that compiles clinical and laboratory
data from patients with Fabry disease; it was established to
further investigate the long-term effects of ERT and the
natural progression of Fabry disease in a larger population.
The purpose of these analyses was to compare key
demographic and clinical characteristics of untreated Fabry
Registry patients in Latin America (LATAM) to that of
untreated patients in the rest of the world (ROW).
Methods
All patients with Fabry disease are eligible to enroll in the
Fabry Registry, regardless of age, gender, symptoms, or
whether or not they are receiving ERT from any commercial
source. Patient and physician participation is voluntary and
all patients sign informed consent forms that have been
reviewed and approved by local Institutional Review Boards/
Ethics Committees. The Fabry Registry provides participat-
ing physicians with a recommended schedule of key clinical
and laboratory assessments (http://www.fabryregistry.com).
However, treating physicians determine the actual frequency
of assessments according to a patient’s individualized needs.
Fabry Registry patients in LATAM included those in
Argentina, Brazil, Chile, Colombia, Mexico, Peru, Uru-
guay, and Venezuela. Patients in the ROW included all
Fabry Registry patients except those in LATAM.
These analyses include data reported to the Fabry
Registry as of October 1, 2010. Clinical parameters
included in the analysis were chronic kidney disease
(CKD) stage, urine protein to creatinine ratio, and left
ventricular posterior wall thickness. Data were collected
from treatment-naïve patients or, if a patient was treated,
baseline data were analyzed (i.e., prior to the initiation of
ERT). Patients whose ERT status was not reported to the
Fabry Registry (7 men and 1 woman in LATAM) were not
included in the clinical event analyses. Clinical parameter
data were ascertained prior to and up to 1 month after the
first agalsidase beta infusion, among adults who ever
received agalsidase beta as a source of ERT (18 years
old at the time of first infusion).
Clinical events that occurred prior to the initiation of ERT
or in untreated patients were included in these analyses.
Cardiovascular clinical events were defined as myocardial
infarction, cardiac syncope, congestive heart failure, angina
pectoris, or significant cardiac procedures (e.g. pacemaker or
other implantable cardiac device placement, bypass, stent
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placement, valve replacement, transplantation), or arrhyth-
mias. Arrhythmias may have been reported to the Fabry
Registry as cardiovascular events, or detected by ECG in a
follow-up visit or reported in a patient’s medical history.
Cerebrovascular events were defined as stroke. Renal events
were defined as receiving chronic dialysis (40 days or
longer) or kidney transplantation. Estimated glomerular
filtration rate (eGFR) was calculated in mL/min/1.73 m2
from serum creatinine values, using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
(Levey et al. 2009).
To better understand the population of patients from
LATAM, demographic characteristics of the patients enrolled
in LATAM were compared to that of the patients enrolled in
the Fabry Registry in the ROW. Tests of the null hypothesis
of equal distributions between the cohorts were conducted
by the t-test. Statistical analyses were performed using
SAS statistical software version 9.1 (SAS Institute Inc.,
Cary, NC). Demographics and clinical characteristics of the
cohorts are presented using summary statistics. An alpha-




As of October 1, 2010, 333 patients were enrolled in the
Fabry Registry within LATAM and 3,419 patients were
enrolled in the ROW. Enrollment in the Fabry Registry in
LATAM has steadily increased since the first patient was
enrolled in this region in 2002 (Fig. 1).
Demographics
Table 1 shows that patients in LATAM were significantly
younger than patients enrolled in the ROW. As of October
1, 2010, the mean age of men in LATAM was 35.5 years
versus 39.2 years for men in the ROW (p ¼ 0.0054); the
mean age of women in LATAM was 37.8 years versus
43.6 years for women in the ROW (p < 0.0001). Thirteen
percent of Fabry Registry patients enrolled in LATAM were
children (<18 years old as of October 1, 2010), compared
to 11% of patients in the ROW. The mean age at the time
Fabry disease was diagnosed was similar among patients in
LATAM and patients in the ROW by gender, but men
tended to be diagnosed at a younger age than women in
both populations (Table 1).
ERT Treatment Status
A substantially smaller percentage of women in LATAM
have ever received ERT, compared to LATAM men (19%
versus 67%), as shown in Fig. 2. Among both genders,
patients in LATAM were less likely to receive ERT than
patients in the ROW. Seventy percent of LATAM men have
received ERT, compared to 80% of men in the ROW
(p ¼ 0.0008); 19% of LATAM women have received ERT,























Number of Patients Enrolled in LATAM
Fig. 1 Enrollment in the Fabry Registry within LATAM by year. Data shown represent cumulative enrollment of LATAM patients in the Fabry
Registry as of December 31 of each year except 2010, which shows enrollment as of October 1, 2010
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Clinical Events
Clinical events were evaluated in the 325 patients from
LATAM who had a known ERT status. Thirty-one percent
of men (50 of 159) and 22% of women (37 of 166) in
LATAM reported experiencing a significant cardiovascu-
lar, renal, or cerebrovascular event, as defined in
Methods. The mean age at the time of the first clinical
event was 35  12.6 years in men and 44  12.3 years in
women. Cardiovascular events were the most common
type of initial clinical event among men and women in
LATAM.
Table 1 Summary of demographic characteristics of Fabry registry patients in LATAM and the ROW
LATAM ROW
Males Females Males Females
Patients in the Registry, n 166 167 1679 1740
Current Age (years), n 166 167 1678 1739
Mean  SD 35.5  13.71a 37.8  17.81b 39.2  16.81 43.6  17.87
Median (min, max) 34.4 (5, 78) 36.2 (5, 85) 41.4 (1, 85) 44.5 (1, 90)
Age distribution, n (%)
Pediatric (<18 years) 17 (10.2) 27 (16.2) 210 (12.5) 151 (8.7)
Adult (18 years) 149 (89.8) 140 (83.8) 1,468 (87.4) 1,588 (91.3)
Unknown 0 0 1 (0.1) 1 (0.1)
Age at diagnosis of FD (years), n 161 160 1,662 1676
Mean  SD 28.6  13.35 32.3  17.15 27.3  17.28 33.6  18.16
Median (min, max)c 28.3 (2, 62) 30.7 (0, 77) 25.3 (0, 81) 32.8 (0, 82)
Data shown represent that reported to the Fabry Registry as of October 1, 2010.
a p ¼ 0.0054 for men in LATAM versus men in the ROW, by t-test
b p < 0.0001 for women in LATAM versus women in the ROW, by t-test







































Fig. 2 ERT treatment status among men and women enrolled in the
Fabry Registry in LATAM and in the ROW. Percentages were
calculated based on the number of patients who reported ever receiving
ERT from any source, excluding patients whose ERT status was not
reported to the Fabry Registry. The numbers above each bar represent
the number of patients who had reported receiving ERT/total number of
patients in each category. For men, LATAM vs ROW p ¼ 0.0008; for
women, LATAM vs ROW p < 0.0001, by Chi-square test
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Cardiovascular Manifestations
As shown in Table 2, 19% of men (30 of 159) and 21% of
women (34 of 166) in LATAM reported a cardiovascular
event, at a mean age of 38 and 46 years, respectively. The
most common type of cardiovascular event was arrhythmia
(any type), which was reported by 16% of men (26 of 159)
and 19% of women (32 of 166). Arrhythmias included those
reported to the Fabry Registry as cardiovascular events as well
as those detected during ECG exams or reported in a patient’s
medical history. Less common cardiovascular events included
significant cardiac procedures (8 of 159 men [5%] and 2 of
166 women [1%]), myocardial infarction (5 of 159 men [3%]
and no women), angina pectoris (4 of 159 men [3%] and 3 of
166 women [2%]), and heart failure (1 of 159 men [0.6%] and
1 of 166 women [0.6%]). Echocardiographic exam data were
reported for 163 patients in LATAM. Among these, 18%
percent of men (29 of 72) and 15% of women (25 of 91)
exhibited left ventricular hypertrophy (LVH).
Renal Manifestations
Fifteen percent of men in LATAM (24 of 159) had a renal
event (kidney transplant or chronic dialysis), at a mean age
of 36  10.9 years (Table 2). Two percent of women in
LATAM (4 of 166) had a renal event, at a mean age of
41  6.8 years. Among these patients, 10 of the 24 men
and 2 of the 4 women had kidney transplants.
Cerebrovascular Manifestations
Five percent of men (8 of 159) and 2% of women (3 of
166) in LATAM reported having a stroke, at a mean age of
41  14.4 years and 40  8.4 years, respectively. One
percent of men (2 of 159) and 5% of women (8 of 166)
reported a transient ischemic attack (TIA).
Pre-Treatment Clinical Characteristics
Among the adult Fabry Registry patients in LATAM who
reported receiving agalsidase beta treatment, 115 had reported
some type of baseline echocardiographic and/or renal data to
the Fabry Registry. Prior to beginning agalsidase beta
treatment, among patients with available data, 38% of men
(15 of 40) and 35% of women (7 of 20) exhibited left
ventricular hypertrophy (Table 3). This is lower than the
percentage of adults in the rest of the world who had left
ventricular hypertrophy prior to beginning agalsidase beta
treatment (57% of men and 48% of women, Table 3).
Baseline renal function data (CKD stage as determined by
eGFR) were available for 84 adult patients who later
received ERT with agalsidase beta (Table 3). Prior to
beginning treatment, 19 of 62 adult men in LATAM (31%)
were in CKD Stages 3–5 (eGFR <60 mL/min/1.73 m2).
Four of 22 adult Latin American females (18%) were in
CKD Stages 3–5 prior to beginning treatment. These are
similar to the percentages of men and women in the ROW
Table 2 Summary of clinical events and age at first clinical event
Males Females
Number of patients 159 166
Patients reporting any type of clinical event n (%) 50 (31.4) 37 (22.3)
Age at first event (years) Mean (SD) 35.4 (12.58) 44.3 (12.31)
Median (min, max) 36.3 (0, 66) 47.2 (13, 71)
Patients reporting cardiovascular event n (%) 30 (18.9) 34 (20.5)
Age at first cardiovascular event (years) Mean (SD) 37.8 (15.19) 45.5 (12.50)
Median (min, max) 42.5 (0, 73) 47.6 (13, 71)
Patients reporting renal event n (%) 24 (15.1) 4 (2.4)
Age at first renal event (years) Mean (SD) 35.6 (10.93) 41.4 (6.84)
Median (min, max) 35.9 (19, 66) 39.6 (36, 51)
Patients reporting stroke event n (%) 8 (5.0) 3 (1.8)
Age at first stroke event (years) Mean (SD) 41.2 (14.40) 40.1 (8.42)
Median (min, max) 39.6 (24, 74) 42.3 (31, 47)
Data are from LATAM patients who had reported whether or not they had ever received ERT. All data were collected prior to initiation of ERT or
are from patients who had not received ERT. Patients whose ERT status was unknown (7 men and 1 woman) were excluded from these analyses.
Data shown represent that reported to the Fabry Registry as of October 1, 2010
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who were in CKD Stages 3–5 before beginning agalsidase
beta treatment (Table 3). Relatively few patients in LATAM
had pre-treatment urinary protein data reported to the Fabry
Registry; 9 of 21 men and 2 of 9 women reported a urinary
protein to creatinine ratio  1 g/g prior to beginning
agalsidase beta treatment.
Discussion
As the largest registry that tracks clinical data for patients
with Fabry disease, the Fabry Registry is a unique source of
valuable information about this disorder. The objective of
these analyses was to better characterize the growing
population of Fabry Registry patients in LATAM.
Enrollment in LATAMhas steadily increased over the past
8 years, with 333 patients enrolled in LATAM as of October
1, 2010. Compared to Fabry Registry patients in the ROW, a
higher percentage of Fabry Registry patients in LATAM are
children and the overall mean current age is younger in
LATAM than in the ROW. It is possible that larger average
family size in LATAM compared to the ROW could
contribute to this difference, as diagnosis of one family
member could lead to the screening of a higher number of
younger family members. However, the younger current age
in LATAM versus the ROW was not accompanied by a
corresponding difference in age at diagnosis. It is not clear
why a statistically significant difference was not observed in
age at diagnosis, but there is a great deal of variation and a
large standard deviation in the reported age at diagnosis. In
any case, the high percentage of young patients enrolled in
the Registry is very encouraging, as it suggests that
physicians in LATAM are diagnosing Fabry disease in young
patients. However, it is also important to regularly monitor
these young patients; children in LATAM tend to have
clinical data reported to the Fabry Registry less frequently
than adults (Fabry Registry database).
As in the ROW, women in LATAM were less likely to
receive ERT than men. Although some women have
relatively mild symptoms of Fabry disease, others experi-
ence substantial manifestations of Fabry disease, including
serious clinical events (Wilcox et al. 2008). Within
LATAM, 37 of 166 women had a clinical event during
the natural history period (i.e., prior to initiating any ERT).
Overall, Fabry Registry patients in LATAM were less likely
to have received ERT than patients in the ROW. This may
be related to the fact that ERT became widely commercially
available earlier in many countries in the ROW than in
LATAM and may also be a reflection of differences in
access to healthcare.
Table 3 Summary of pre-treatment renal and cardiac characteristics of adult Fabry registry patients in LATAM and the ROW
Adults in Latin America (LATAM) Adults inrest of world
Males Females Males Females
Adult patients who ever received agalsidase beta, N 86 29 1001 511
Pre-treatment left posterior wall thickness (LPWT), n (%) 40 20 572 343
LPWT < 12 mm 25 (62.5) 13 (65.0) 248 (43.4) 178 (51.9)
LPWT  12 mm, indicating left ventricular hypertrophy (LVH) 15 (37.5) 7 (35.0) 324 (56.6) 165 (48.1)
Age at first report of LVH (years)
Mean (SD) 34.5 (11.94) 44.8 (12.49) 39.4 (11.5) 46.5 (12.2)
Median (min, max) 32.7 (20, 69) 47.9 (21, 72) 39.2 (18, 81) 47.3 (18, 76)
Pre-Treatment CKD Stage, n (%) 62 22 840 440
Stage 1 (90 mL/min/1.73 m2) 32 (51.6) 10 (45.5) 383 (45.6) 210 (47.7)
Stage 2 (60–< 90 mL/min/1.73 m2) 11 (17.7) 8 (36.4) 187 (22.3) 153 (34.8)
Stage 3 (30–< 60 mL/min/1.73 m2) 8 (12.9) 3 (13.6) 147 (17.5) 56 (12.7)
Stage 4 (15–< 30 mL/min/1.73 m2) 4 (6.5) 1 (4.5) 55 (6.5) 11 (2.5)
Stage 5 (<15 mL/min/1.73 m2) 7 (11.3) 0 68 (8.1) 10 (2.3)
Pre-treatment urine protein to creatinine ratio, n (%) 21 9 452 280
<0.3 g/g 6 (28.6) 5 (55.6) 157 (34.7) 120 (42.9)
0.3–< 1 g/g 6 (28.6) 2 (22.2) 113 (25.0) 63 (22.5)
1–< 3 g/g 4 (19.0) 0 129 (28.5) 62 (22.1)
3 g/g 5 (23.8) 2 (22.2) 53 (11.7) 35 (12.5)
Data are from adults who ever received agalsidase beta (18 years old at the time of the first infusion) and reflect data available as of 01 October
2010. Data obtained prior to and up to 1 month after the first agalsidase beta infusion were included in these calculations. eGFR (estimated
glomerular filtration rate) was calculated in mL/min/1.73 m2 from serum creatinine values, using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation
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Overall, 31% of men and 22% of women in LATAM
experienced a clinical event during the natural history
period, which is similar to what has been reported for the
global Fabry Registry population (31% of men and 20% of
women) (Wilcox et al. 2008). The most common initial
events reported by both genders were cardiovascular
events, which is also similar to what has been reported for
the overall Fabry Registry population (Wilcox et al. 2008).
A retrospective chart review of 447 untreated patients also
reported that cardiovascular events were the most common
type of event in both genders (Schiffmann et al. 2009). The
most common type of cardiovascular event reported was
arrhythmia; overall, 18% of patients in LATAM reported
some type of cardiac arrhythmia. This is consistent with
other reports describing arrhythmias as the most common
and earliest type of cardiac manifestation of Fabry disease
(Linhart et al. 2007; Schiffmann et al. 2009; Wilcox et al.
2008). Among the LATAM patients who received agalsi-
dase beta and for whom baseline echocardiographic data
were reported, a smaller percentage displayed left ventricu-
lar hypertrophy, compared to patients in the ROW. This
may be related to the fact that the patients in LATAM were
younger than patients in the ROW.
Fifteen percent of men and 2% of women in LATAM
required renal replacement therapy, through either dialysis
or a kidney transplant, at a mean age of 36 years for men
and 41 years for women. This is remarkably similar to what
has been reported for the overall Fabry Registry population.
Ortiz et al. reported that 14% of untreated men and 2% of
untreated women in the global Fabry Registry required
dialysis or a kidney transplant at a men age of 39 years
(men) and 40 years (women) (Ortiz et al. 2010). Unfortu-
nately, relatively few patients in LATAM reported detailed
renal clinical data to the Fabry Registry, in terms of eGFR
and/or urinary protein levels. The data that are available
suggest that similar percentages of patients in LATAM and
in the ROW exhibit CKD Stage 3 or higher prior to
initiating ERT (approximately 30%).
A small percentage of patients in LATAM reported a
stroke: 5% of men and 2% of women at a mean age of
41 years and 40 years, respectively. This is generally
consistent or slightly lower than what has been reported for
the overall Fabry Registry population; Sims et al. reported
that 7% of untreated men and 4% of untreated women
experienced a stroke (Sims et al. 2009). In the global Fabry
Registry population, the age at first stroke was 40 for men
and 46 for women (Sims et al. 2009).
Many of the manifestations of Fabry disease resemble
other, more common disorders. Consequently, patients with
Fabry disease are frequently not diagnosed until long after
the onset of symptoms. In 2007, the average time from
symptom onset to diagnosis among Fabry Registry patients
was 14 years for men and 16 years for women (Wilcox
et al. 2008). This is concerning, because Fabry disease is
treatable and there is considerable evidence that ERT is
most effective when it is initiated early, before the onset of
substantial organ damage (Banikazemi et al. 2007; Germain
et al. 2007; Warnock et al. 2011). Increased awareness of
Fabry disease among the general medical community will
facilitate prompt diagnosis and reduce delays in treatment,
both in LATAM and in the ROW. In addition, physicians
should be encouraged to obtain a thorough medical history
for all patients and to screen potentially affected family
members.
Various limitations are associated with analyzing obser-
vational data from a disease registry, particularly for rare
diseases with small numbers of patients. For example, not
all patients have reported all types of clinical data to the
Fabry Registry. While a schedule of recommended clinical
assessments is provided, treating physicians determine the
actual type and frequency of assessments according to
individual patients’ needs. In addition, some patients report
data to the Fabry Outcome Survey, a smaller registry that
tracks patients with Fabry disease; the baseline clinical
characteristics of patients enrolled in the two registries may
differ.
In summary, enrollment in the Fabry Registry within
LATAM has increased substantially over the past several
years, which may indicate increased awareness of Fabry
disease in the LATAM region and increased interest in
contributing data to this important database. Over time, as
the Fabry Registry continues to collect clinical data from
patients in LATAM, we will gain a better understanding of
the nature of Fabry disease and treatment outcomes in this
patient population.
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Synopsis
The Fabry Registry has collected data from 333 Latin
American patients with Fabry disease; demographic and
clinical characteristics of these patients were compared to
Fabry Registry patients in the rest of the world.
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